By Doug Macron
New Zealand's Genesis Research and Development last week said that it is once again asking its shareholders to make additional investments in the company, this time to give the cash-strapped firm the resources to enable its subsidiary, Solirna Biosciences, to reach a key milestone with its single-stranded RNAi technology.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
